Cancer Prevention Agent Development Program: Early Phase Clinical Research
Awarded Award Notice Posted
- Solicitation number
- N01CN05014-69
- Agency
- National Institutes of Health Department of Health and Human Services
- Awarded
- to University Of Wisconsin System
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSN261201200033I Federal IDV award
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
Notice text
4 versions
Update #4 · Latest ·
Added: Sep 22, 2012 3:30 pm
A total of five contracts were awarded. In addition to the University of Arizona noted above, awards were made to the following:
Award 2
Contract Award Number: HHSN261201200032I
Contractor: Mayo Clinic
200 First Street SW
Rochester, MN 55905
Award 3
Contract Award Number: HHSN261201200033I
Contractor: Board of Regents of the University of Wisconsin System
21 North Park Street, Suite 6401
Madison, WI 53715-1218
Award 4
Contract Award Number: HHSN261201200034I
Contractor: The University of Texas, MD Anderson Cancer Center
1515 Holcombe Boulevard
Houston, Texas, 77030
Award 5
Contract Award Number: HHSN261201200035I
Contractor: Northwestern University
633 Clark Street
Evanston, Illinois 60208-1110
Update #3 ·
Added: Mar 04, 2011 8:50 am
Modified: Mar 25, 2011 2:37 pmTrack Changes
The RFP is now available and attached to this notice.
Request for Proposals (RFP) N01CN05014-69, Cancer Prevention Agent Development Program: Early Phase Clinical Research
Contracting Office Address
Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), Office of Acquisitions, 6120 Executive Boulevard, Suite 600, Room 6002, Bethesda, MD 20892-7195.
Note: This synopsis follows a Sources Sought notice that was released on February 12, 2010 under HHS-NIH-NCI-PCPSB-5014-29
Description
The National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Prevention (DCP), Phase I/II Cancer Prevention Clinical Trials Program is seeking proposals from qualified organizations who have the capacity to conduct early phase clinical trials and accrue a specified number of subjects per year.
The main objective of the contracts awarded as a result of the solicitation will be the conduct of multiple early phase clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents. The contracts will provide essential clinical trials infrastructure and laboratory support: (1) To efficiently design and conduct early phase clinical trials of cancer preventive agents of various classes; (2) To characterize the biological effects of new cancer preventive agents on their defined molecular targets as well as on multiple endpoints associated with carcinogenesis and correlate these effects with clinically relevant endpoints; and (3) To develop scientific insights into the mechanisms of cancer prevention by the agents examined and to continue to develop novel potential markers as determinants of response. Each Contractor shall be able to initiate multiple clinical trials per year accruing a minimum of 75 total study participants to Phase 0 - Phase II clinical trials, with the emphasis on Phase II trials. The agents to be studied will be DCP-specified cancer preventive agents as well as agents obtained by the Contractor. The size of each trial will vary depending on phase of development and organ site. However, each Contractor shall have the capacity to perform studies in multiple organs (i.e., more than 2) and is strongly encouraged to establish an infrastructure composed of one or more collaborating institutions to enhance their capability to conduct these clinical trials and to provide specific technical expertise for biomarker studies.
The proposed acquisition will be a full and open competition. The contracts for the project are currently held by:
Institution and Contract Number-
University of Arizona, Tucson, AZ N01-CN-35158
University of California-Irvine, Orange, CA N01-CN-35160
Northwestern University, Chicago, IL N01-CN-35157
Mayo Clinic Foundation, Rochester, MN N01-CN-35000
University of Texas M. D. Anderson Cancer Center, Houston, TX N01-CN-35159
University of Wisconsin-Madison, Madison, WI N01-CN-35153
The North American Industry Classification System (NAICS) code is 541712. The NCI intends to award multiple cost reimbursement type contracts for a base period of five years plus two, one year options on or about June 2012. Request for Proposal number N01CN05014-69 will be available on or about March 21, 2011, with a due date for receipt of proposals on or about July 21, 2011.
POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. ALL INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO THE CONTRACTING OFFICER LISTED AS THE POINT OF CONTRACT HEREIN.
Point of Contact
Donna Perry-Lalley, Contracting Officer, Phone 301-435-3776, Fax 301-402-8579, Email perryd@mail.nih.gov
Alternate Point of Contact
Virginia DeSeau, Contracting Officer, Phone 301-435-3778, FAX 301-402-8579, Email deseauv@mail.nih.gov
Update #2 ·
Added: Mar 04, 2011 8:50 am
Modified: Mar 04, 2011 9:10 amTrack Changes
Pre-Solicitation
Request for Proposals (RFP) N01CN05014-69, Cancer Prevention Agent Development Program: Early Phase Clinical Research
Contracting Office Address
Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), Office of Acquisitions, 6120 Executive Boulevard, Suite 600, Room 6002, Bethesda, MD 20892-7195.
Note: This synopsis follows a Sources Sought notice that was released on February 12, 2010 under HHS-NIH-NCI-PCPSB-5014-29
Description
The National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Prevention (DCP), Phase I/II Cancer Prevention Clinical Trials Program is seeking proposals from qualified organizations who have the capacity to conduct early phase clinical trials and accrue a specified number of subjects per year.
The main objective of the contracts awarded as a result of the solicitation will be the conduct of multiple early phase clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents. The contracts will provide essential clinical trials infrastructure and laboratory support: (1) To efficiently design and conduct early phase clinical trials of cancer preventive agents of various classes; (2) To characterize the biological effects of new cancer preventive agents on their defined molecular targets as well as on multiple endpoints associated with carcinogenesis and correlate these effects with clinically relevant endpoints; and (3) To develop scientific insights into the mechanisms of cancer prevention by the agents examined and to continue to develop novel potential markers as determinants of response. Each Contractor shall be able to initiate multiple clinical trials per year accruing a minimum of 75 total study participants to Phase 0 - Phase II clinical trials, with the emphasis on Phase II trials. The agents to be studied will be DCP-specified cancer preventive agents as well as agents obtained by the Contractor. The size of each trial will vary depending on phase of development and organ site. However, each Contractor shall have the capacity to perform studies in multiple organs (i.e., more than 2) and is strongly encouraged to establish an infrastructure composed of one or more collaborating institutions to enhance their capability to conduct these clinical trials and to provide specific technical expertise for biomarker studies.
The proposed acquisition will be a full and open competition. The contracts for the project are currently held by:
Institution and Contract Number-
University of Arizona, Tucson, AZ N01-CN-35158
University of California-Irvine, Orange, CA N01-CN-35160
Northwestern University, Chicago, IL N01-CN-35157
Mayo Clinic Foundation, Rochester, MN N01-CN-35000
University of Texas M. D. Anderson Cancer Center, Houston, TX N01-CN-35159
University of Wisconsin-Madison, Madison, WI N01-CN-35153
The North American Industry Classification System (NAICS) code is 541712. The NCI intends to award multiple cost reimbursement type contracts for a base period of five years plus two, one year options on or about June 2012. Request for Proposal number N01CN05014-69 will be available on or about March 21, 2011, with a due date for receipt of proposals on or about July 21, 2011.
POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. ALL INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO THE CONTRACTING OFFICER LISTED AS THE POINT OF CONTRACT HEREIN.
Point of Contact
Donna Perry-Lalley, Contracting Officer, Phone 301-435-3776, Fax 301-402-8579, Email perryd@mail.nih.gov
Alternate Point of Contact
Virginia DeSeau, Contracting Officer, Phone 301-435-3778, FAX 301-402-8579, Email deseauv@mail.nih.gov
Update #1 ·
Added: Mar 04, 2011 8:50 am
Pre-Solicitation
Request for Proposals (RFP) N01CN05014-69, Cancer Prevention Agent Development Program: Early Phase Clinical Research
Contracting Office Address
Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), Office of Acquisitions, 6120 Executive Boulevard, Suite 600, Room 6002, Bethesda, MD 20892-7195.
Note: This synopsis follows a Sources Sought notice that was released on February 12, 2010 under HHS-NIH-NCI-PCPSB-5014-29
Description
The National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Prevention (DCP), Phase I/II Cancer Prevention Clinical Trials Program is seeking proposals from qualified organizations who have the capacity to conduct early phase clinical trials and accrue a specified number of subjects per year.
The main objective of the contracts awarded as a result of the solicitation will be the conduct of multiple early phase clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents. The contracts will provide essential clinical trials infrastructure and laboratory support: (1) To efficiently design and conduct early phase clinical trials of cancer preventive agents of various classes; (2) To characterize the biological effects of new cancer preventive agents on their defined molecular targets as well as on multiple endpoints associated with carcinogenesis and correlate these effects with clinically relevant endpoints; and (3) To develop scientific insights into the mechanisms of cancer prevention by the agents examined and to continue to develop novel potential markers as determinants of response. Each Contractor shall be able to initiate multiple clinical trials per year accruing a minimum of 75 total study participants to Phase 0 - Phase II clinical trials, with the emphasis on Phase II trials. The agents to be studied will be DCP-specified cancer preventive agents as well as agents obtained by the Contractor. The size of each trial will vary depending on phase of development and organ site. However, each Contractor shall have the capacity to perform studies in multiple organs (i.e., more than 2) and is strongly encouraged to establish an infrastructure composed of one or more collaborating institutions to enhance their capability to conduct these clinical trials and to provide specific technical expertise for biomarker studies.
The proposed acquisition will be a full and open competition. The contracts for the project are currently held by:
Institution and Contract Number-
University of Arizona, Tucson, AZ N01-CN-35158
University of California-Irvine, Orange, CA N01-CN-35160
Northwestern University, Chicago, IL N01-CN-35157
Mayo Clinic Foundation, Rochester, MN N01-CN-35000
University of Texas M. D. Anderson Cancer Center, Houston, TX N01-CN-35159
University of Wisconsin-Madison, Madison, WI N01-CN-35153
The North American Industry Classification System (NAICS) code is 541712. The NCI intends to award multiple cost reimbursement type contracts for a base period of five years plus two, one year options on or about June 2012. Request for Proposal number N01CN05014-69 will be available on or about March 21, 2011, with a due date for receipt of proposals on or about July 21, 2011.
POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. ALL INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO THE CONTRACTING OFFICER LISTED AS THE POINT OF CONTRACT HEREIN.
Attachments
| File | Type | Posted |
|---|---|---|
| Amendment_3_Attachment_1_InformationAndPhysicalAccessSecurity.pdf | ||
| amendment3.pdf | ||
| Transcript_of_Preproposal_Conference_Held_04272011.pdf | ||
| ATTACHMENT_1_PACKAGINGANDDELIVERYOFTHEPROPOSAL_05042011.pdf | ||
| amendment2.pdf | ||
| amendment1.pdf | ||
| Attachment_1_PACKAGING_AND_DELIVERY_OF_PROPOSALS_revised.pdf | ||
| N01CN05014-69.pdf | ||
| RFPAttachmentNondisclosure.pdf | ||
| Attachment_3_Statement_of_Work.pdf | ||
| Attachment_1_PACKAGING_AND_DELIVERY_OF_PROPOSALS.pdf |
Show all 11
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity